Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
Medigene ( (DE:MDG1) ) has issued an update.
Medigene AG has announced the execution of the first tranche of a Standby Equity Purchase Agreement with Yorkville Advisors Global, LP. This move will increase Medigene’s share capital by EUR 150,000 through the issuance of 150,000 new shares, exclusively subscribed by Yorkville. The adjustment aims to bolster financial resources and potentially enhance the company’s market position.
More about Medigene
Medigene AG is an oncology platform company that specializes in the research and development of T cell receptor (TCR)-guided therapies for cancer treatment. The company is listed on the Frankfurt Stock Exchange under the symbol MDG1 and operates within the Prime Standard market segment.
YTD Price Performance: 58.20%
Average Trading Volume: 679
Technical Sentiment Consensus Rating: Buy
Current Market Cap: €11.5M
Find detailed analytics on MDG1 stock on TipRanks’ Stock Analysis page.
